Cannara Stock Based Compensation To Revenue from 2010 to 2024
| LOVE Stock | CAD 0.75 0.05 6.25% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 0.02418187 | Current Value 0.023 | Quarterly Volatility 0.25782594 |
Check Cannara Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cannara Biotech's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 181 K or Interest Expense of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.71, Dividend Yield of 0.0 or PTB Ratio of 0.66. Cannara financial statements analysis is a perfect complement when working with Cannara Biotech Valuation or Volatility modules.
Cannara | Stock Based Compensation To Revenue |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.